Answers are grounded in this paper and cite their sources.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy and exhibits aggressive behavior. Huge ICC (tumor diameter ≥ 10 cm) poses particular challenges and liver resection (LR) is the only potentially curative option, but reliable preoperative tools to identify candidates who benefit from surgery are lacking. This study retrospectively analyzed 469 patients with huge ICC treated between January 2010 and August 2024. Independent preoperative predictors of overall survival (OS) were identified by Cox proportional hazards model and further incorporated into a nomogram. The predictive performance of this nomogram was evaluated by the concordance index (C-index) and calibration plots, and the clinical utility was assessed by the decision curve analysis (DCA). Survival differences between groups were compared by using Kaplan-Meier analysis with the log-rank test. Propensity score matching (PSM) was employed to minimize covariate imbalances in the comparisons. Among the 469 patients, median OS was 15.3 months (95% confidence interval [CI], 12.9–17.9) in the LR group ( n = 370) and 10.1 months (95% CI, 8.4–12.2) in the chemotherapy group ( n = 99) (log-rank P < 0.001). LR patients were randomly divided into a training group ( n = 259) and a validation group ( n = 111). Six independent factors of OS were incorporated into the nomogram with good discrimination (C-index = 0.71 and 0.72 in the training and validation groups, respectively) and accurate calibration curves. The C-indices of the nomogram were higher than those of the TNM system (0.63 and 0.65, P < 0.001 for both). DCA demonstrated the net clinical benefit of the nomogram. LR patients were stratified into low-, moderate-, and high-risk subgroups according to nomogram points, and the OS did not differ significantly between high-risk subgroup and chemotherapy group, either before or after PSM. A preoperative nomogram that effectively stratifies huge ICC patients into distinct survival-risk subgroups was established. It is an accurate tool to assist in treatment decision-making for huge ICC. ClinicalTrials.gov, NCT02526771.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: